| CAS NO: | 35607-66-0 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 100mg | 电议 |
| Cas No. | 35607-66-0 |
| 别名 | 头孢西丁 |
| Canonical SMILES | O=C(C(N12)=C(COC(N)=O)CS[C@]2([H])[C@@](NC(CC3=CC=CS3)=O)(OC)C1=O)O |
| 分子式 | C16H17N3O7S2 |
| 分子量 | 427.45 |
| 溶解度 | DMSO: 100 mg/mL (233.95 mM) |
| 储存条件 | 4°C, away from moisture and light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Cefoxitin is a broad-spectrum, second-generation cephalosporin with antibacterial activity. Cefoxitin is effective against a wide variety of infections caused by gram-positive or gram-negative aerobes as well as by anaerobic bacteria[1][2]. Cefoxitin has good activity against gram-positive bacteria. The MICs for several gram-positive pathogens are in the range of 1-6 μg/mL[1].Cefoxitin has shown high efficacy killing B. burgdorferi at concentration of 1.25 µM/mL[3]. Cefoxitin (20 mg/kg; i.p.; daily; for 5 days) effectively kills B. burgdorferi in vivo C3H/HeN mouse model[3]. Animal Model: Four-week-old female C3H/HeN mice[3] [1]. E O Stapley, et al. Cefoxitin and cephamycins: microbiological studies. Rev Infect Dis. Jan-Feb 1979;1(1):73-89. [2]. R N Brogden, et al. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979 Jan;17(1):1-37. [3]. Venkata Raveendra Pothineni, et al. In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease. Drug Des Devel Ther. 2018; 12: 2915-2921. |
m.cnreagent.com